DiaSys Corporation Announces New Product Registration in China.

Business Editors/Health/Medical Writers

WATERBURY, Conn.--(BUSINESS WIRE)--Dec. 16, 2003

DiaSys Corporation (AMEX: DYX) a global healthcare company today announced that the company's strategic business partner in China, Hua Sin Science Co., Ltd. has successfully completed the registration process In China for DiaSys' new R/S 500 urine sediment workstation. The R/S 500 is specifically designed to standardize and automate urine sediment testing for smaller volume laboratories.

Richard Sledziona, Executive Vice President of DiaSys Corporation said, "The R/S 500 was specifically developed in order to provide affordable, safe, standardized automation for smaller volume laboratories. While small volume laboratories are cognizant of the need to provide safe, standardized testing; their ability to do this has always been difficult because the high cost of automated laboratory instruments. The R/S was developed at the recommendation of our partner Hua Sin to address this specific need for more than 50,000 smaller hospitals in China."

Mrs. Lui Qian, General Manager of Hua Sin Science Co., Ltd., stated, " The launch of R/S 500 will not only improve the technical level of smaller hospitals in China, but also bring a huge business opportunity for both sides. We also hope DiaSys could continually develop more new products that are suitable to the Chinese market so as to increase the technical levels of clinical laboratories in China."

Gregory Witchel, Chief Executive Officer of DiaSys Corporation, said, " We are excited about the tremendous potential that this product affords. Hua Sin has already purchased 100 of the new R/S 500 workstations, with additional ongoing orders forecasted for 2004."

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.